Clinical Trial

Evaluation of Botulinum TOXin Type A in the Treatment of Buerger's Disease

Study acronym: BETOX
Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The main objective is to assess the feasibility of treatment by injecting botulinum toxin A into the hand or foot of patients with signs of critical ischemia secondary to Buerger's disease. The injection of botulinum toxin A is carried out at the end of a single session during an hospitalization. Furthermore, tolerance and effects on the disease are evaluated at 1, 3 and 6 months post injections.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2023-01-16; most recent amendment 2026-07-21.
Trial Details
NCT Number NCT05698979
Lead Sponsor University Hospital, Toulouse
Conditions Buerger Disease, Raynaud Syndrome
Enrollment 8 participants
Start Date 2027-01-01
Primary Completion 2028-02 (estimated)
Study Completion 2028-02 (estimated)
Updated on ClinicalTrials.gov 2026-07-23